1 citations
,
January 2020 in “IRIS UNIMORE (University of Modena and Reggio Emilia)” Aminexil clinical 5 effectively reduces hair loss and is well-tolerated.
3 citations
,
July 2024 in “Skin Research and Technology” Asthma may increase the risk of alopecia areata.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib helps long-term hair regrowth in severe alopecia areata patients.
3 citations
,
September 2022 in “Journal of the American Academy of Dermatology” Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
5 citations
,
January 2024 in “Journal of Cancer” The treatment combination is effective and generally safe for lung cancer.
April 2025 in “Scientific Reports” Astragaloside A may help fight lung cancer by targeting specific proteins.
3 citations
,
June 2023 in “Journal of cosmetic dermatology” A new drug, abrocitinib, helped a child with severe hair loss regrow hair.
April 2024 in “Pharmaceuticals” Bimatoprost helps with hair growth and eye conditions but can be costly and have side effects.
3 citations
,
September 2016 in “Dermatologic Therapy” Doxycycline helps prevent skin issues from erlotinib in lung cancer patients.
September 2023 in “Forum Dermatologicum” Dutasteride injections can help treat hair loss in men and women.
STS01 1% effectively promotes hair regrowth with minimal side effects.
April 2026 in “Cosmetics” Astragalus plants may improve skin health and have anti-aging benefits.
May 2025 in “Dermatology Online Journal” Erlotinib can cause excessive eyelash growth.
9 citations
,
June 2014 in “Nutrition and Cancer” Eclipta alba extract may work as an anticancer agent and help reverse drug resistance.
March 2025 in “JAAD reviews.” Bimatoprost effectively improves eyelashes in chemotherapy patients.
February 2026 in “PubMed” Microneedles with Astragalus and minoxidil improve hair growth.
6 citations
,
February 2023 in “Journal of the American Academy of Dermatology” Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.
March 2005 in “Journal of the American Academy of Dermatology” Bexarotene 1% topical gel helped some patients with alopecia areata regrow hair.
2 citations
,
April 2019 in “Dermatologic Therapy” A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.
15 citations
,
November 2020 in “Pharmaceutics” Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.
17 citations
,
December 2013 in “Journal of Investigative Dermatology Symposium Proceedings” Bimatoprost is safe and effective for treating eyelash loss caused by chemotherapy.
August 2023 in “Journal of Investigative Dermatology” Dutasteride may help treat frontal fibrosing alopecia.
January 2024 in “Faculty of 1000 Research Ltd” Tazarotene gel may be more effective for acne than adapalene gel.
13 citations
,
January 2017 in “Annals of dermatology/Annals of Dermatology” Simvastatin/ezetimibe may help some patients with severe alopecia areata regrow hair.
July 2025 in “Clinical Medicine” Oral betamethasone works faster than oral tofacitinib for hair regrowth in alopecia areata.
6 citations
,
January 2015 in “Journal of clinical & experimental dermatology research” The combination therapy may be more effective for mild alopecia areata, especially in patients with allergies.
June 2024 in “International journal of nanomedicine” Azelaic acid micro/nanocrystals, especially with ultrasound and salicylic acid, greatly improve acne treatment.
1 citations
,
June 2019 in “Journal of Cutaneous Immunology and Allergy” Squaric acid dibutylester can cause severe skin reactions in people with allergies.
February 2026 in “Reports — Medical Cases Images and Videos” Upadacitinib may help regrow hair in children with alopecia areata and is generally safe.
December 2023 in “Journal of health and rehabilitation research” Oral Apremilast effectively treats alopecia areata in most patients.